<DOC>
	<DOCNO>NCT00003843</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irinotecan treating patient colorectal cancer .</brief_summary>
	<brief_title>Irinotecan Treating Patients With Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine frequency genetic polymorphism UGT1 Hispanics colorectal cancer . - Determine pharmacokinetics irinotecan metabolite , SN38 SN38G , associate genotype UGT1 clinical toxicity . - Determine whether genetic polymorphism UGT1 associate clinical toxicity pharmacokinetics/pharmacodynamics irinotecan patient unresectable colorectal cancer treat irinotecan . - Determine response , time progression , survival patient UGT1A1 polymorphism treat irinotecan . OUTLINE : Genomic DNA isolate blood sample patient analyze UGT1 polymorphism . Patients stratify accord UGT1 genotype ( homozygous wild type v heterozygous abnormal allele v homozygous abnormal allele ) . Patients receive irinotecan 90 minute weekly 4 week . Treatment repeat every 6 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : Approximately 28 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven advanced disseminated colorectal cancer Progressive disease fluorouracil base chemotherapy OR Recurrence disease within 12 month adjuvant therapy fluorouracil No known CNS metastases carcinomatous meningitis PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : At least 12 week Hematopoietic : Granulocyte count great 1500/mm^3 Platelet count great 100,000/mm^3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT great 3 time ULN ( great 5 time ULN liver involve ) Renal : Creatinine great 2.0 mg/dL Calcium great 12.0 mg/dL Cardiovascular : No myocardial infarction within past 6 month No congestive heart failure require therapy Neurologic : No severe psychiatric disorder No history seizures Other : No active uncontrolled infection HIV negative No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No uncontrolled diabetes mellitus ( random blood sugar 200 mg/dL great ) No severe concurrent disease Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Prior oxaliplatin allow No prior irinotecan topotecan Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent phenytoin , phenobarbital , antiepileptic prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>